Biogenera proudly took part in the BIO International Convention 2025, one of the world’s largest and most influential events for the biotechnology industry, held in Boston from June 16 to 19.
The convention brought together thousands of biotech and pharma companies, investors, and institutions from around the globe — offering a unique platform for strategic partnering, innovation exchange, and international collaboration.
Bringing Biogenera to the Global Stage
Representing Biogenera at the event were Massimiliano Cesarini (CEO) and Federico Ragni (Head of Business Development), who engaged in partnering meetings, thematic panels, and networking activities within the partneringOne® platform.
This was an opportunity to share updates on:
- The preparation of the Phase I clinical trial for BGA002
- • The potential of the proprietary MyGenera™ platform
- The promise of anti-gene PNA-based therapies, designed to act directly at the DNA level of disease-causing genes
Accelerating Innovation Through Collaboration
BIO International confirmed the strategic importance of international engagement for clinical-stage biotech companies like Biogenera. With a busy agenda of high-level meetings and growing visibility, the event enabled valuable connections with biotech peers, investors, CROs, and co-development players.
Looking Ahead
Participation in the BIO International Convention is part of a broader strategy to expand Biogenera’s global presence. In the coming months, the company will continue to attend leading industry events while finalizing regulatory and manufacturing steps ahead of the upcoming Phase I trial.
English 
Italian